Correlation Between Enveric Biosciences and Crispr Therapeutics
Can any of the company-specific risk be diversified away by investing in both Enveric Biosciences and Crispr Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enveric Biosciences and Crispr Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Enveric Biosciences and Crispr Therapeutics AG, you can compare the effects of market volatilities on Enveric Biosciences and Crispr Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enveric Biosciences with a short position of Crispr Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enveric Biosciences and Crispr Therapeutics.
Diversification Opportunities for Enveric Biosciences and Crispr Therapeutics
0.1 | Correlation Coefficient |
Average diversification
The 3 months correlation between Enveric and Crispr is 0.1. Overlapping area represents the amount of risk that can be diversified away by holding Enveric Biosciences and Crispr Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crispr Therapeutics and Enveric Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enveric Biosciences are associated (or correlated) with Crispr Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crispr Therapeutics has no effect on the direction of Enveric Biosciences i.e., Enveric Biosciences and Crispr Therapeutics go up and down completely randomly.
Pair Corralation between Enveric Biosciences and Crispr Therapeutics
Given the investment horizon of 90 days Enveric Biosciences is expected to under-perform the Crispr Therapeutics. In addition to that, Enveric Biosciences is 2.69 times more volatile than Crispr Therapeutics AG. It trades about -0.01 of its total potential returns per unit of risk. Crispr Therapeutics AG is currently generating about 0.01 per unit of volatility. If you would invest 5,211 in Crispr Therapeutics AG on August 26, 2024 and sell it today you would lose (423.00) from holding Crispr Therapeutics AG or give up 8.12% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Enveric Biosciences vs. Crispr Therapeutics AG
Performance |
| Timeline |
| Enveric Biosciences |
| Crispr Therapeutics |
Enveric Biosciences and Crispr Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Enveric Biosciences and Crispr Therapeutics
The main advantage of trading using opposite Enveric Biosciences and Crispr Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enveric Biosciences position performs unexpectedly, Crispr Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will offset losses from the drop in Crispr Therapeutics' long position.| Enveric Biosciences vs. Eliem Therapeutics | Enveric Biosciences vs. HCW Biologics | Enveric Biosciences vs. Scpharmaceuticals | Enveric Biosciences vs. Milestone Pharmaceuticals |
| Crispr Therapeutics vs. Eliem Therapeutics | Crispr Therapeutics vs. HCW Biologics | Crispr Therapeutics vs. Scpharmaceuticals | Crispr Therapeutics vs. Milestone Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Complementary Tools
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |